Storage Stability
Salusin-alpha is a 28-amino-acid peptide derived from prosalusin, an endogenous precursor encoded by the TORSIN2A-related gene. Together with its sister peptide salusin-beta, it regulates cardiovascular function, with salusin-alpha predominantly exerting bradycardic and hypotensive effects in contrast to the pro-atherogenic salusin-beta.
Mechanism of Action
- Induces bradycardia and hypotension when administered IV, acting primarily at cardiac level rather than via vasodilation
- Inhibits angiotensin II-stimulated aldosterone synthesis in adrenocortical cells, contributing to natriuretic effects
- Reduces sympathetic nerve activity centrally; acts on hypothalamic cardiovascular centers when administered ICV
- Suppresses vascular smooth muscle cell proliferation and foam cell formation, opposing the pro-atherogenic salusin-beta
- Modulates insulin secretion from pancreatic beta cells at pharmacological doses
Research Findings
- Salusin-alpha plasma levels reduced in patients with hypertension and coronary artery disease vs healthy controls
- IV salusin-alpha in rats produced dose-dependent bradycardia (20-40% HR reduction) and blood pressure lowering
- Salusin-alpha inhibited macrophage-to-foam cell conversion in vitro, suggesting anti-atherogenic role
- Ratio of salusin-beta/salusin-alpha elevated in metabolic syndrome; may predict cardiovascular risk
- ICV administration studies revealed central cardiovascular regulation distinct from peripheral effects
Research Protocols
- Animal cardiovascular studies: 0.3-3 nmol/kg IV bolus in anesthetized rats; measure HR and BP by telemetry
- In vitro foam cell assay: 10-100 nM salusin-alpha with macrophages and oxidized LDL
- No clinical protocols; biomarker measurement only in human studies
- ELISA-based plasma measurement: commercially available research kits
Interactions
- Salusin-beta: functional antagonist in many cardiovascular and atherogenic parameters
- Angiotensin II: salusin-alpha opposes Ang II-driven aldosterone release and vasoconstriction
- ACE inhibitors: additive blood pressure lowering in animal models
Safety Profile
Endogenous peptide. Not approved or used therapeutically. Reduced plasma levels correlate with cardiovascular disease. Research interest in restoring salusin-alpha signaling as a cardioprotective strategy.
Legal & Regulatory
Research peptide; not approved as therapeutic
Ready to dose Salusin-Alpha?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
Categories:
Endogenous PeptideCardiovascular PeptideBradycardic AgentAnti-AtherogenicProsalusin Derivative
More in Muscle & Anabolic
View all →